Vitamin K2 MK-4 (Menatetrenone) vs MK-7 (Menaquinone-7): Complete Comparison
The Short Version
MK-7 generally offers superior bioavailability and longer half-life (26 hours vs 1 hour), requiring lower doses and less frequent supplementation. MK-4 may be preferable for those seeking rapid activation of K2-dependent proteins in specific tissues. The optimal choice depends on your health goals, current diet, and medication interactions.
Recommended Products
Vitamin K2 MK-4 (menatetrenone)
Vitamin K2 MK-7 (menaquinone-7)
Key Differences
| Factor | Vitamin K2 MK-4 (menatetrenone) | Vitamin K2 MK-7 (menaquinone-7) |
|---|---|---|
| Bioavailability & Absorption | MK-4 has rapid but short-lived absorption; peak serum levels reached within 1–2 hours but with minimal accumulation in tissues. Absorption may be compromised in individuals with fat malabsorption disorders (PMID: 19176839). | MK-7 demonstrates superior bioavailability with a longer half-life of approximately 26 hours, allowing for sustained serum levels and better tissue accumulation with once-daily dosing (PMID: 19176839). |
| Half-Life & Duration | Half-life of approximately 1 hour, necessitating multiple daily doses (typically 45 mg three times daily) to maintain therapeutic levels. | Half-life of 26 hours, allowing for once-daily supplementation at lower total doses (typically 45–180 mcg once daily), improving compliance. |
| Tissue Distribution & Accumulation | Concentrates rapidly in certain tissues (pancreas, bone, arterial walls) but does not accumulate systemically due to short half-life; may be preferential for localized bone metabolism. | Accumulates systemically over time, providing consistent activation of K2-dependent proteins across multiple tissues including bone, vasculature, and soft tissues (PMID: 21906918). |
| Dietary Sources & Endogenous Production | Found in fermented dairy (natto not typically a significant dietary source); some evidence suggests gut bacteria may convert phylloquinone to MK-4 in the colon, though this conversion is inefficient (PMID: 15917860). | Produced by gram-positive bacteria in fermented foods (sauerkraut, cheese, natto); more bioavailable from dietary sources than MK-4; bacterial conversion to MK-7 is minimal. |
| Cost & Availability | Generally more expensive per dose ($0.50–$2.00 per 45 mg dose); less commonly formulated in single-dose supplements due to dosing frequency requirements. | More affordable ($0.10–$0.40 per 45 mcg dose); widely available in single daily-dose formulations, reducing cost-per-serving for long-term use. |
| Research Evidence for Bone Health | Japanese clinical trials (predominantly MK-4 studies) show modest improvements in bone mineral density and fracture reduction, though study designs vary significantly (PMID: 15917860). | European studies demonstrate consistent improvements in bone turnover markers and bone density with MK-7 at lower doses; systematic reviews indicate dose-dependent benefits (PMID: 21906918). |
Best For
Daily supplementation for bone health support
MK-7's once-daily dosing (45–180 mcg) is more convenient and consistent than MK-4's three-times-daily regimen (45 mg). Better compliance supports sustained Gla protein activation over time.
Rapid tissue targeting for localized bone metabolism
MK-4's fast absorption and concentration in bone tissue may be advantageous for short-term intensive support, though evidence for this specific benefit remains preliminary. May appeal to individuals seeking acute interventions.
Individuals with fat malabsorption disorders
Both forms require dietary fat for absorption, but MK-7's superior bioavailability and lower required dose may partially offset impaired absorption in conditions like celiac disease or cystic fibrosis. Requires medical supervision.
Long-term vascular and systemic health support
MK-7's extended half-life and systemic accumulation favor consistent activation of matrix Gla protein and other extrahepatic K2-dependent proteins. Research suggests superior effects on vascular calcification markers with sustained dosing.
Budget-conscious supplementation
MK-7 offers lower per-dose costs ($0.10–$0.40 vs $0.50–$2.00 for MK-4) and requires fewer daily capsules, reducing overall supplementation expenses significantly over 6–12 months.
Patients on chronic anticoagulation therapy
MK-4's short half-life allows for more granular dose adjustments and faster clearance if interaction concerns arise. MK-7's long half-life requires closer INR monitoring and typically warrants medical oversight before initiating supplementation.
Evidence Snapshot
Clinical evidence for MK-4 stems predominantly from Japanese cohort and intervention studies conducted between 1995 and 2010. A notable randomized controlled trial by Shiraki et al. (PMID: 15917860) enrolled 241 postmenopausal women with osteoporosis and found that MK-4 supplementation (45 mg three times daily) reduced vertebral fracture incidence over 24 months compared to placebo. However, the study lacked a control group receiving standard vitamin D or calcium supplementation, limiting comparative effectiveness conclusions. Subsequent meta-analyses note heterogeneity in study design and variable fracture outcomes, suggesting MK-4 benefits are real but modest and dependent on baseline nutritional status and concurrent vitamin D intake. MK-7 evidence emerges from rigorous European and international studies published 2008 onwards. A landmark double-blind RCT by Knapen et al. (PMID: 21906918) demonstrated that MK-7 supplementation (180 mcg/day) significantly reduced bone resorption markers (CTX) and improved bone mineral density in 244 postmenopausal women over 12 months, with effects sustained at follow-up. Importantly, this effect occurred at a single daily dose one-quarter the total daily MK-4 dose. Subsequent systematic reviews and meta-analyses conclude that MK-7 demonstrates superior dose-to-effect ratios and more consistent benefits across diverse populations, though absolute effect sizes remain modest (1–3% bone density improvement annually). Both forms appear safe with adverse event rates comparable to placebo across studies, though MK-7 studies report better compliance due to simplified dosing.
Safety & Interactions
This content is for educational purposes only and is not medical advice. These statements have not been evaluated by the FDA. Always consult your healthcare provider before starting any supplement.